Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antisense Technology
Egr-1 inhibition reverses the transformation of prostate cancer cells
September 1st, 2003
Egr-1 inhibition reverses the transformation of prostate cancer cells. According to recent research published in the journal Oncogene, "transcription factor early growth response-1 (Egr-1) is a crucial regulator of cell growth, differentiation and survival. Several observations suggest that Egr-1 is growth promoting in prostate cancer cells and that blocking its function may impede cancer progression. To test this hypothesis, we developed phosphorothioate antisense oligonucleotides that efficiently inhibit Egr-1 expression without altering the expression of other family members Egr-2, Egr-3 and Egr-4." "In TRAMP mouse-derived prostate cancer...
Source: Health & Medicine Week (2003-09-01)
|
